- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05060237
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BF-200 ALA (Ameluz®) in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp With Photodynamic Therapy (PDT)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Alliance Dermatology & MOHS Center
-
Phoenix, Arizona, United States, 85006
- Medical Dermatology Specialists
-
-
Colorado
-
Greenwood Village, Colorado, United States, 80111
- Dermatology Practice
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Laser and Skin Surgery Center of Indiana
-
-
New York
-
Rochester, New York, United States, 14623
- Skin Search of Rochester, Inc
-
Victor, New York, United States, 14564
- Rochester Dermatologic Surgery
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- Clinical Research Center of the Carolinas
-
-
Texas
-
Houston, Texas, United States, 77056
- Austin Institute for Clinical Research
-
Pflugerville, Texas, United States, 78660
- Austin Institute for Clinical Research Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willingness and ability of subjects to provide informed consent and sign the Health Insurance Portability and Accountability Act (HIPAA) form. A study-specific informed consent and HIPAA form must be obtained in writing prior to starting any study procedures.
- Subjects with mild to severe clinically confirmed AK lesions (according to Olsen) on the face and/or scalp. In case of severe AK lesions, a biopsy must be taken for confirmation of diagnosis. At least 8 mild to moderate AK lesions with a diameter of ≥4 mm must be present in the treatment field. The treatment field (continuous or in several patches) totaling about 60 cm2 must be located within one effective illumination area. The AK lesions should be clearly distinguishable, without restrictions on the distance between lesions. Lesions should have a minimal distance of 1 cm between the lesion margin and the border of the treatment field.
- All sexes, ≥18 years of age.
- Willingness and ability to comply with study procedures, particularly willingness to receive a PDT session and to undergo 2 mm punch biopsy/biopsies in case of severe AK lesion(s) at the screening visit.
- Subjects with good general health or with clinically stable medical conditions will be permitted to be included in the study. Subjects with clinically stable medical conditions will be permitted for inclusion into the study if not using prohibited medication.
- Willingness to stop the use of moisturizers and any other non-medical topical treatments within the treatment field at least 24 h prior to the visits.
- Acceptance to abstain from extensive sunbathing and the use of a solarium or tanning beds during the study.
- For female subjects with reproductive potential: Negative serum pregnancy test.
- For female subjects with reproductive potential: Effective contraception at screening visit and throughout the study.
Exclusion Criteria:
- Any known history of hypersensitivity to ALA, porphyrins or excipients of BF-200 ALA.
- History of soy or peanut allergy.
- Subjects with sunburn or other possible confounding skin conditions (e.g. wounds, irritations, bleeding or skin infections) inside or in close proximity (<10 cm distance) to the treatment field.
Clinically significant (CS) medical conditions making implementation of the protocol or interpretation of the study results difficult or impairing subject's safety such as:
- Presence of photodermatoses or porphyria
- Metastatic tumor or tumor with high probability of metastasis
- Infiltrating skin neoplasia (suspected or known)
- Unstable cardiovascular disease (New York Heart Association class III, IV)
- Unstable hematologic (including myelodysplastic syndrome), hepatic, renal, neurologic, or endocrine condition
- Unstable collagen-vascular condition
- Unstable gastrointestinal condition
- Immunosuppressive condition
- Presence of clinically significant inherited or acquired coagulation defect
- Clinical diagnosis of atopic dermatitis, Bowen's disease, basal cell carcinoma, eczema, psoriasis, rosacea, squamous cell carcinoma, other malignant or benign tumors inside or in close proximity (<10 cm distance) to the treatment field.
- Presence of strong artificial pigmentation (e.g. tattoos) or any other abnormality that may impact lesion assessment or light penetration in the treatment field.
- Any physical therapy such as cryosurgery, laser therapy, electrodessication, microdermabrasion, surgical removal of lesions, curettage, or treatment with chemical peels such as trichloroacetic acid inside or in close proximity (<10 cm distance) to the treatment field within 4 weeks prior to screening.
Any of the topical treatments defined below within the designated periods prior to screening:
- Topical treatment with ALA or ALA esters (e.g. methyl aminolevulinic acid (MAL)) or an investigational drug in- and outside the treatment field within 8 weeks.
- Topical treatment with immunosuppressive, cytostatic or cytotoxic drugs inside or in close proximity (<10 cm distance) to the treatment field within 8 weeks.
- Start of topical administration of a medication with hypericin or other drugs with phototoxic or photoallergic potential inside or in close proximity (<10 cm distance) to the treatment field within 4 weeks. Subjects may, however, be eligible if such medication was applied for more than 4 weeks prior to screening without evidence of an actual phototoxic/photoallergic reaction.
Any use of the systemic treatments within the designated periods prior to screening:
- Cytostatic or cytotoxic drugs within 6 months.
- Immunosuppressive therapies or use of ALA or ALA esters (e.g. MAL) within 12 weeks.
- Drugs known to have major organ toxicity within 8 weeks or an investigational drug.
- Interferon or glucocorticosteroids within 6 weeks.
- Start of intake of medication with hypericin or systemically acting drugs with phototoxic or photoallergic potential within 8 weeks prior to screening. Subjects may, however, be eligible if such medication was taken in for more than 8 weeks prior to the screening visit without evidence of an actual phototoxic/photoallergic reaction.
- Breast feeding women.
- Suspicion of drug or alcohol abuse.
- Subjects unlikely to comply with protocol, e.g. inability to return for visits, unlikely to complete the study, or inappropriate in the opinion of the investigator.
- A member of study site staff or sponsor staff directly involved in the conduct of the protocol or a close relative thereof.
- Simultaneous participation in another clinical study.
Dosing day exclusion criteria:
At Visit 2 (baseline, PDT-1)
Subjects with sunburn or other possibly confounding skin conditions (e.g. wounds, irritations, bleeding or skin infections) inside or in close proximity (<10 cm distance) to the treatment field.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BF-200 ALA
Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid). One single photodynamic therapy (PDT). |
Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT): Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and severity of adverse events (AEs), serious AEs (SAEs), and treatment emergent adverse events (TEAEs).
Time Frame: through study completion, an average 6 weeks
|
TEAEs are defined as all AEs with onset or worsening after treatment with IMP up to Visit 5 (approx.
28 days post treatment)
|
through study completion, an average 6 weeks
|
Duration of TEAEs including the breakdown of severity category (mild, moderate, severe).
Time Frame: from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
|
Assessment of new lesions (AK, NMSC such as BCC, SCC or Bowens disease, and melanoma) if they occur inside the treatment field
Time Frame: from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
|
Assessment of new lesions (AK, NMSC, and melanoma) if they occur around the treatment field at a distance of <10 cm
Time Frame: from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
|
Application site skin reactions during and post PDT, assessed by the investigator
Time Frame: from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
Application site skin reaction categories: discharge, erosion, erythema, exfoliation, fissure, induration, oedema, scabbing, skin flaking, ulceration, vesicles, other; severity of AE: mild, moderate or severe
|
from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
Application site discomfort during and post PDT, reported by the subjects
Time Frame: from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
Application site discomfort categories: burning, hyperaesthesia, pain, paraesthesia, pruritus, stinging, warmth, other; severity of AE: mild, moderate or severe
|
from treatment day (day 1) up to Visit 5 (approx. 28 days post treatment)
|
Application site pain during illumination
Time Frame: at treatment day (day 1) after end of illumination
|
Assessed by the subjects using an 11-point numeric rating scale, where a score of 0 means "no pain" and a score of 10 means "worst imaginable pain".
|
at treatment day (day 1) after end of illumination
|
Changes in blood pressure (systolic and diastolic)
Time Frame: at all clinical visits through study completion, on average 6 weeks
|
[mmHg]
|
at all clinical visits through study completion, on average 6 weeks
|
Changes in pulse rate
Time Frame: at all clinical visits through study completion, on average 6 weeks
|
[beats/min]
|
at all clinical visits through study completion, on average 6 weeks
|
Changes in body temperature
Time Frame: at all clinical visits through study completion, on average 6 weeks
|
[°C]
|
at all clinical visits through study completion, on average 6 weeks
|
Investigation of clinical chemistry parameters
Time Frame: At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)
|
Findings which differ from reference range and are considered to be clinically significant are to be reported
|
At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)
|
Investigation of hematology parameters
Time Frame: At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)
|
Findings which differ from reference range and are considered to be clinically significant are to be reported
|
At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)
|
Investigation of urinalysis parameters
Time Frame: At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)
|
Findings which differ from reference range and are considered to be clinically significant are to be reported
|
At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)
|
Physical examination of head, neck, skin, lymph nodes, thorax including heart and lungs, abdomen, and musculoskeletal, peripheral vascular and nervous system status
Time Frame: At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)
|
Abnormal findings, considered to be clinically significant, are to be reported
|
At screening (up to 14 days before treatment) and at Visit 5 (approx. 28 days post treatment)
|
Memory tests
Time Frame: At screening (up to 14 days before treatment) and at Visit 2 (treatment day 1)
|
Including picture- and question-based memory tasks; abnormal findings that are considered clinically significant will be documented
|
At screening (up to 14 days before treatment) and at Visit 2 (treatment day 1)
|
Neurological investigations
Time Frame: At screening (up to 14 days before treatment) and at Visit 2 (treatment day 1)
|
Including investigation of pupils (equality), coordination (finger-nose test), gait (balance), and sensitivity (cheeks, arms, legs); abnormal findings that are considered clinically significant will be documented
|
At screening (up to 14 days before treatment) and at Visit 2 (treatment day 1)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALA-AK-CT018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keratosis
-
PeplinCompletedSeborrheic KeratosisAustralia
-
Aclaris Therapeutics, Inc.CompletedSeborrheic Keratosis (SK)United States
-
DermBiont, Inc.Active, not recruitingA Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic KeratosisSeborrheic KeratosisUnited States
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Pulse Biosciences, Inc.CompletedSeborrheic Keratosis | Lesion SkinUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
DermBiont, Inc.Zepeda DermatologiaActive, not recruitingSeborrheic KeratosisEl Salvador
-
Aclaris Therapeutics, Inc.CompletedSeborrheic KeratosisUnited States
-
Milton S. Hershey Medical CenterCompletedSeborrheic KeratosisUnited States
Clinical Trials on BF-200 ALA and red light LED lamp
-
Biofrontera Bioscience GmbHRecruiting
-
Biofrontera Bioscience GmbHCompleted
-
Biofrontera Bioscience GmbHCompleted
-
Biofrontera Bioscience GmbHCompleted
-
Edward Maytin, MD, PhDDUSA Pharmaceuticals, Inc.CompletedBasal Cell Nevus SyndromeUnited States
-
Biofrontera Bioscience GmbHAccovion GmbHCompleted
-
University of BergenGlamoxCompletedSleep | Sleep Deprivation | Shift-Work Related Sleep DisturbanceNorway
-
Case Comprehensive Cancer CenterThe Cleveland Clinic; Biofrontera, Inc.RecruitingActinic KeratosisUnited States
-
Biofrontera Bioscience GmbHCompleted